The first patient has been dosed in a Phase IIa clinical trial evaluating Oragenics Inc.’s ONP-002 for concussion and mild traumatic brain injury at Mackay Hospital in Australia. This milestone, achieved shortly after site activation on March 31, 2026, follows regulatory approval and represents progress for a potential first-in-class intranasal neurosteroid designed to address underlying brain injury mechanisms.
The trial’s advancement highlights the pursuit of a treatment for a condition with no FDA-approved pharmacological options, targeting a large unmet medical need. Oragenics is expanding trial sites as it works to develop brain-targeted therapeutics through its proprietary intranasal delivery technology. The company’s platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.
ONP-002 is Oragenics’ lead candidate, and the company is working on commencing clinical trials in Australia, with U.S. Phase 2b trials planned to follow. The development of innovative therapies for neurological care remains a key focus for the clinical-stage biotechnology company. More information about the company is available at https://oragenics.com.
The latest news and updates relating to Oragenics are available in the company’s newsroom at https://ibn.fm/OGEN. This development was reported by BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors, which is part of the Dynamic Brand Portfolio at IBN. For more information about BioMedWire, visit https://www.BioMedWire.com.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oragenics Doses First Patient in Phase IIa Trial for Potential Concussion Treatment.